Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2071 to 2080 of 2579 total matches.
What is Going on with Levothyroxine
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001 (Issue 1108)
10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S. Funds—per ...
The media recently reported that the FDA has threatened to withdraw Synthroid from the market, alarming many physicians and patients.
Spinal Manipulation
The Medical Letter on Drugs and Therapeutics • May 27, 2002 (Issue 1131)
-7537
Customer Service:
Toll-free: 1-800-211-2769
Fax: 1-914-632-1733
Web Site: http ...
Spinal manipulation has been used to treat not only back and neck pain, but also many other conditions. A recent commentary questioned its safety.
In Brief: Cetirizine OTC
The Medical Letter on Drugs and Therapeutics • Jan 14, 2008 (Issue 1277)
FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
1
The Medical ...
Cetirizine (Zyrtec, and others) and cetirizine/pseudoephedrine (Zyrtec-D) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children. Cetirizine is the second of the second-generation H1-antihistamines to become available over the counter. Loratadine (Claritin, and others) was the first.Cetirizine has been shown to be more effective than loratadine in suppressing histamine-induced wheals in healthy volunteers (W Carey et al. Drugs Exp Clin Res 2002; 28:243), but no well-controlled clinical trials have established that any...
A Reminder: Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008 (Issue 1291)
freshmen living in dormitories.
1,2
The peak incidence of meningococcal disease, after
early childhood ...
The U.S. Advisory Committee on Immunization Practices has recommended administration of the quadrivalent conjugated polysaccharide meningococcal vaccine (Menactra – Sanofi Pasteur) to all persons 11 to 18 years old, particularly those entering high school and college freshmen living in dormitories.1,2 The peak incidence of meningococcal disease, after early childhood, occurs in the 15-19 year-old age group. The conjugate vaccine is more immunogenic than the meningococcal capsular polysaccharide vaccine (Menommune – Sanofi Pasteur).ADVERSE EFFECTS — The most common adverse reactions with...
In Brief: Exenatide (Byetta) and Pancreatitis
The Medical Letter on Drugs and Therapeutics • Sep 08, 2008 (Issue 1294)
in patients taking exenatide than in patients with
diabetes not taking exenatide is not clear.
1
Given ...
The FDA has issued an update (August 18, 2008; www.fda.gov) on occurrences of acute pancreatitis in patients with diabetes taking exenatide (Byetta – Amylin/Lilly). The latest update, which follows an FDA Alert in October 2007, reports 6 cases of hemorrhagic or necrotizing pancreatitis with 2 deaths in patients taking the drug. Whether pancreatitis occurs more often in patients taking exenatide than in patients with diabetes not taking exenatide is not clear.1Given by subcutaneous injection, exenatide is a synthetic peptide that stimulates release of insulin from pancreatic beta cells.2 It...
Correction: CT Colonography
The Medical Letter on Drugs and Therapeutics • Jan 12, 2009 (Issue 1303)
Colonography (Med Lett Drugs Ther
2008; 50:94)
In Table 1, “Invasive” should be “less” and “more” rather ...
(Med Lett Drugs Ther 2008; 50:94) In Table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively. In the conclusion, CT colonography should be changed to "less invasive" rather than "noninvasive".
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis and Golimumab (Simponi) for Inflammatory Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
.
Golimumab (Simponi) for Inflammatory Arthritis (Med
Lett Drugs Ther 2009; 51:55)
In Table 1 on page 55 ...
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis (Med Lett Drugs Ther 2009; 51:49) - The first word of the title should have been Biennial, not Biannual.
Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55) - In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 (not $3,136.40).
Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55) - In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 (not $3,136.40).
An Expanded Pneumococcal Vaccine (Prevnar 13) for Infants and Children
The Medical Letter on Drugs and Therapeutics • Aug 23, 2010 (Issue 1345)
serotypes
included in PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F
and 23F) and 6 additional serotypes (1, 3, 5 ...
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for
the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces
Prevnar (PCV7). An unconjugated 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 – Merck) is FDA-approved for use in adults.
Capsaicin Patch (Qutenza) for Postherpetic Neuralgia
The Medical Letter on Drugs and Therapeutics • May 30, 2011 (Issue 1365)
or even years.1
STANDARD TREATMENT — Opioids and topical
analgesics such as lidocaine (Lidoderm ...
The FDA has approved a topical 8% patch formulation
of capsaicin (Qutenza – NeurogesX), available only by
prescription, for local treatment of postherpetic neuralgia.
Postherpetic neuralgia occurs after herpes zoster
in about one third of patients ≥60 years old and can
persist for months or even years.
Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain
The Medical Letter on Drugs and Therapeutics • May 02, 2011 (Issue 1363)
,1,2 duloxetine
(Cymbalta – Lilly) has now also been approved for
treatment of chronic ...
Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral
neuropathic pain and fibromyalgia, duloxetine (Cymbalta – Lilly) has now also been approved for
treatment of chronic musculoskeletal pain.